Compare DuPont de Nemours Inc (DD) vs HCA Health Inc (HCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs HCA Health Inc — how do they compare? DuPont de Nemours Inc trades at $131.75 (market cap $17.70B), while HCA Health Inc trades at $443.69 (market cap $95.08B). The key difference: HCA Health Inc is far larger — about 5.4× DuPont de Nemours Inc's market cap, and DuPont de Nemours Inc pays the higher dividend (1.83%). Which is the better fit depends on your goals — on Pluang, investors hold DuPont de Nemours Inc for 89 Days and HCA Health Inc for 76 Days on average.
| DD | HCA | |
|---|---|---|
Market Cap | $17.70B | $95.08B |
Volume | 638,303 | 998,787 |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $545.13 |
52-Week Low | $92.49 | $361.32 |
Typical Hold Time | 89 Days | 76 Days |
Enterprise Value | $19.09B | $145.62B |
Dividend Yield | 1.83% | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $132.48, down 0.6% for the day, with neutral technical signals and mixed fundamentals. The company has beaten earnings estimates for three consecutive quarters but shows declining revenue and negative net income for 2025. Recent innovations include digital tools for sugar separation and sustainable Tyvek materials, while facing legal settlements over PFAS contamination.
Outlook remains cautious with analyst consensus favoring Buy (58.5%) but a price target of $95 below current levels. Key opportunities include margin expansion in healthcare and water technologies, while risks involve ongoing litigation costs, uneven construction demand, and profitability challenges despite recent earnings beats.
HCA Healthcare (HCA) trades at $445.01, up 2.96% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $75.6B in 2025, with net income of $6.78B, and the stock trades at a P/E of 14.73. Analyst consensus is a Buy with a $461.12 price target, though ongoing legal investigations pose a headwind.
The outlook remains positive given solid demand and cost controls, but risks include payer-mix pressure and high debt levels. Upside potential exists if earnings growth continues, but investors should monitor legal developments and interest rate impacts on the leveraged balance sheet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
